Heron Therapeuti
$ 1.31
3.15%
04 Dec - close price
- Market Cap 232,870,000 USD
- Current Price $ 1.31
- High / Low $ 1.32 / 1.20
- Stock P/E N/A
- Book Value 0.04
- EPS -0.10
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA N/A %
- ROE -24.09 %
- 52 Week High 2.68
- 52 Week Low 1.00
About
Heron Therapeutics, Inc. (HRTX), headquartered in San Diego, California, is a pioneering biotechnology firm committed to developing advanced therapies targeting critical unmet needs in pain management and antiemetic care. The company focuses on the research and commercialization of innovative pharmaceutical solutions designed to enhance the quality of life for patients undergoing surgical procedures and cancer treatments. With a strong pipeline and a strategic emphasis on high-demand therapeutic areas, Heron Therapeutics is uniquely positioned to drive meaningful advancements in healthcare, ultimately improving patient outcomes and addressing key challenges in the medical field.
Analyst Target Price
$4.50
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-05 | 2025-08-08 | 2025-05-05 | 2025-03-10 | 2024-11-12 | 2024-08-06 | 2024-05-07 | 2024-03-12 | 2023-11-14 | 2023-08-14 | 2023-05-11 | 2023-03-23 |
| Reported EPS | -0.0361 | -0.02 | 0.0134 | 0.02 | -0.0317 | -0.06 | -0.02 | -0.07 | -0.17 | -0.35 | -0.27 | -0.17 |
| Estimated EPS | -0.01 | -0.01 | -0.01 | -0.025 | -0.03 | -0.04 | -0.09 | -0.16 | -0.29 | -0.23 | -0.2 | -0.28 |
| Surprise | -0.0261 | -0.01 | 0.0234 | 0.045 | -0.0017 | -0.02 | 0.07 | 0.09 | 0.12 | -0.12 | -0.07 | 0.11 |
| Surprise Percentage | -261% | -100% | 234% | 180% | -5.6667% | -50% | 77.7778% | 56.25% | 41.3793% | -52.1739% | -35% | 39.2857% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: HRTX
2025-10-29 22:01:00
Heron Therapeutics, Inc. announced the appointment of Thomas Cusack to its Board of Directors, effective October 27, 2025, as part of a Cooperation Agreement with Rubric Capital Management LP. Mr. Cusack brings over 20 years of experience in corporate finance, investment management, and corporate governance from roles at Starboard Value LP, Barclays Capital, and Lehman Brothers. His appointment is expected to enhance Heron's strategic direction and corporate governance, particularly in advancing its therapeutic innovations in acute care and oncology.
2025-10-29 17:58:00
Heron Therapeutics, Inc. announced the appointment of Thomas Cusack to its Board of Directors, effective October 27, 2025. Mr. Cusack brings over 20 years of experience in investment management and corporate finance, including a significant tenure as Managing Director at Starboard Value LP. His appointment is pursuant to a Cooperation Agreement with Rubric Capital Management LP and is expected to contribute significantly to Heron's strategic efforts.
2025-10-15 20:32:16
Heron Therapeutics stockholders approved proposals to issue common stock exceeding 19.99% of outstanding shares. These approvals are linked to future conversions of convertible senior unsecured promissory notes and Series A Convertible Preferred Stock. The company, which focuses on pain management and cancer care, faces financial challenges despite strong revenue growth.
2025-10-15 20:18:00
Heron Therapeutics shareholders have approved the issuances of convertible securities. This decision was made during a recent shareholder meeting.
2025-08-15 07:45:00
Heron Therapeutics, Inc. has adopted a Tax Benefits Preservation Plan, specifically a Section 382 rights plan, to protect its substantial net operating loss carryforwards (NOLs). This plan aims to deter any single investor or group from acquiring 4.99% or more of the company's stock, which could trigger an "ownership change" under Section 382 of the Internal Revenue Code and limit the use of these valuable tax assets. The company's NOLs, totaling approximately $1.37 billion as of December 31, 2024, are crucial for offsetting future taxable income and supporting its growth strategy.
2025-08-14 00:00:00
Latham & Watkins advised Hercules Capital on a comprehensive capital restructuring for Heron Therapeutics, a commercial-stage biotechnology company. This restructuring aims to enhance Heron's financial flexibility, reduce debt, and support long-term growth through a new senior credit facility totaling US$150 million, an exchange agreement for existing notes, new convertible notes, and a private placement. The multidisciplinary team from Latham & Watkins was led by partners Dan Van Fleet and Haim Zaltzman for finance, Eric Rice for capital markets, and Eric Cho for tax matters.
